Published on
Updated
Reading 2 min.
On Thursday, the National Medicines Agency (ANSM) suspended the use of an illegal patch, tested on hundreds of Parkinson’s and Alzheimer’s patients.
On Thursday, the ANSM decided to suspend advertising and operation by the company Sodeval of the ImuPatch product, supposed to prevent and treat several neurological diseases such as Parkinson’s, Alzheimer’s and multiple sclerosis.
350 patients treated in wild clinical trials
The patch in question, called ImuPatch, would prevent, according to the company Sodeval, “many so-called autoimmune diseases, mainly neurodegenerative“.
On its site, on Linkedin and via mailings, the company claims that its transdermal patch – composed of Valentonin and 6-Methoxy-Harmalan, two molecules close to melatonin – can preventively and curatively treat:
“Parkinson’s disease, Alzheimer’s disease, Multiple Sclerosis, Lewy body disease, Charcot disease, epilepsy, Sleep disorders, psychotic disorders (Schizophrenics, Nervous depressions, etc.), thyroid insufficiencies , myopathies, all cancers for preventive and curative purposes, type I and II diabetes, diseases due to immune deficiency: AIDS, inflammatory diseases, etc..”.
In parallel with these allegations, the Joséfa fund had carried out in September 2019, a wild clinical trial on more than 350 vulnerable people to whom the said patch had been administered… in exchange for which they had received a check for a value including “between 1000 and 2,500 euros“.
The ANSM ends the exploitation and advertising of the product
An illegal exercise, led within the Abbey of Sainte-Croix (Poitiers) by Professor Henri Joyeux, a personality decried by the scientific community for his anti-vaccine positions – and by Professor Jean-Bernard Fourtillan, director of the Valentonine operating company (Sodeval SAS) behind the patent on the skin patch.
The ANSM has, in fact, decided to take a health policy decision.in order to prevent the exploitation and advertising of the ImuPatch product by the company Sodeval“.
“HASno marketing authorization, nor even any prior approval for advertising, although provided for by the Public Health Code, has been granted by the ANSM to the company Sodeval for the Imupatch product. The targeted patients, suffering from serious pathologies, whose state of health may also represent increased vulnerability, must be treated with proven treatments, the benefits and risks of which have been evaluated by the health authorities.“, she emphasizes.
Serious health risks
“The lack of guarantee as to the origin, quality, effectiveness and safety of this patch outside the pharmaceutical circuit represents risks for the health of patients.“, underlines the agency, in a press release.
Indeed, the two molecules used, close to melatonin, have significant side effects.